SG11201507257RA - Methods of treating dyskinesia and related disorders - Google Patents

Methods of treating dyskinesia and related disorders

Info

Publication number
SG11201507257RA
SG11201507257RA SG11201507257RA SG11201507257RA SG11201507257RA SG 11201507257R A SG11201507257R A SG 11201507257RA SG 11201507257R A SG11201507257R A SG 11201507257RA SG 11201507257R A SG11201507257R A SG 11201507257RA SG 11201507257R A SG11201507257R A SG 11201507257RA
Authority
SG
Singapore
Prior art keywords
methods
related disorders
treating dyskinesia
dyskinesia
treating
Prior art date
Application number
SG11201507257RA
Other languages
English (en)
Inventor
John Ciallella
John Gruner
Andrew G Reaume
Michael S Saporito
Original Assignee
Melior Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Discovery Inc filed Critical Melior Discovery Inc
Publication of SG11201507257RA publication Critical patent/SG11201507257RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/041,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
SG11201507257RA 2013-03-15 2014-03-14 Methods of treating dyskinesia and related disorders SG11201507257RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786714P 2013-03-15 2013-03-15
PCT/US2014/029827 WO2014145126A2 (fr) 2013-03-15 2014-03-14 Méthodes de traitement de la dyskinésie et de troubles associés

Publications (1)

Publication Number Publication Date
SG11201507257RA true SG11201507257RA (en) 2015-10-29

Family

ID=51538415

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707560TA SG10201707560TA (en) 2013-03-15 2014-03-14 Methods of treating dyskinesia and related disorders
SG11201507257RA SG11201507257RA (en) 2013-03-15 2014-03-14 Methods of treating dyskinesia and related disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201707560TA SG10201707560TA (en) 2013-03-15 2014-03-14 Methods of treating dyskinesia and related disorders

Country Status (15)

Country Link
US (5) US9051312B2 (fr)
EP (1) EP2970160B1 (fr)
JP (1) JP6605447B2 (fr)
KR (3) KR20210113429A (fr)
CN (1) CN105209445B (fr)
AU (1) AU2014233334B2 (fr)
BR (1) BR112015023116A2 (fr)
CA (1) CA2904539C (fr)
EA (1) EA032064B1 (fr)
HK (1) HK1220453A1 (fr)
IL (1) IL241114B (fr)
MX (1) MX2015013151A (fr)
SG (2) SG10201707560TA (fr)
WO (1) WO2014145126A2 (fr)
ZA (1) ZA201506705B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986891C (fr) * 2015-05-26 2022-01-04 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions et methodes pour le traitement de la maladie de parkinson et de troubles associes
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138094A1 (fr) 2019-04-17 2020-10-22 Compass Pathfinder Limited Procedes de traitement des troubles de l'anxiete, des troubles de la cephalee et des troubles de l'alimentation au moyen de psilocybine
EP4282862A1 (fr) * 2022-05-25 2023-11-29 Irbm S.P.A. Inhibiteurs de flavivirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1496056A (fr) * 1964-06-08 1967-09-29 Takeda Chemical Industries Ltd Nouveaux composés chimiques du type sydnonimine
GB1262830A (en) 1970-06-10 1972-02-09 Vni Khim Farmatsevtichesky I I Novel sydnonimine derivative
CA1097659A (fr) 1976-11-25 1981-03-17 Roald A. Altshuler Derives n-acyl de la sydnonimine et methode de preparation
US4277609A (en) * 1979-08-31 1981-07-07 American Home Products Corporation Sydnone imines
US4446322A (en) 1980-07-29 1984-05-01 American Home Products Corporation Hydroxyl protected 3-(2-hydroxy-2-phenylethyl)-N-[(phenylamino)carbonyl]sydnone imine intermediates
US4324897A (en) * 1980-10-02 1982-04-13 American Home Products Corporation 1,2,3 Oxadiazolium salts
DE3921796A1 (de) * 1989-07-03 1991-01-17 Cassella Ag Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
AU3632393A (en) * 1992-03-24 1993-10-21 Cassella Aktiengesellschaft Use of sydnonimines to treat erectile dysfunction
IL160133A0 (en) * 2002-05-30 2004-06-20 King Pharmaceuticals Res & Dev Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US8691853B2 (en) * 2007-03-14 2014-04-08 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
ES2582660T3 (es) * 2007-03-14 2016-09-14 Caliper Life Sciences, Inc. Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
US20110207718A1 (en) * 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
ES2537387T3 (es) * 2009-12-04 2015-06-08 Perkinelmer, Inc. Método de uso de inhibidores de la recaptación de la dopamina y sus análogos para el tratamiento de los síntomas de la diabetes y el retraso o la prevención de las afecciones patológicas asociadas con la diabetes
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders

Also Published As

Publication number Publication date
US20140371231A1 (en) 2014-12-18
KR20210113429A (ko) 2021-09-15
US20170042894A1 (en) 2017-02-16
EA032064B1 (ru) 2019-04-30
US12048697B2 (en) 2024-07-30
IL241114B (en) 2019-07-31
US11351169B2 (en) 2022-06-07
US20220331320A1 (en) 2022-10-20
HK1220453A1 (zh) 2017-05-05
US9402830B2 (en) 2016-08-02
EA201591480A1 (ru) 2016-03-31
ZA201506705B (en) 2017-09-27
CN105209445B (zh) 2018-01-23
EP2970160A4 (fr) 2017-01-25
US20150231116A1 (en) 2015-08-20
AU2014233334A1 (en) 2015-10-08
KR102301073B1 (ko) 2021-09-10
BR112015023116A2 (pt) 2017-07-18
JP2016514698A (ja) 2016-05-23
KR20150132391A (ko) 2015-11-25
WO2014145126A3 (fr) 2014-12-18
US20190328736A1 (en) 2019-10-31
NZ712291A (en) 2020-10-30
SG10201707560TA (en) 2017-11-29
CA2904539A1 (fr) 2014-09-18
CA2904539C (fr) 2022-05-03
US10188651B2 (en) 2019-01-29
JP6605447B2 (ja) 2019-11-13
US9051312B2 (en) 2015-06-09
EP2970160A2 (fr) 2016-01-20
CN105209445A (zh) 2015-12-30
IL241114A0 (en) 2015-11-30
AU2014233334B2 (en) 2018-07-19
EP2970160B1 (fr) 2020-11-11
WO2014145126A2 (fr) 2014-09-18
KR20240004497A (ko) 2024-01-11
MX2015013151A (es) 2016-04-11

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HK1218506A1 (zh) 治療黑素瘤的方法
EP2970317A4 (fr) Composés pyrimido-diazépinone et procédés de traitement de troubles
HK1224307A1 (zh) 原毒素- 變體及其使用方法
EP2976094A4 (fr) Méthodes de traitement de troubles métaboliques
HK1214773A1 (zh) 纖維化和癌症的治療方法
HK1220453A1 (zh) 治療運動障礙和相關病症的方法
IL241096B (en) Treatment methods
EP2961401A4 (fr) Méthodes de traitement de l'ototoxicité
HK1224220A1 (zh) 治療神經退化性失調的方法
GB201315673D0 (en) Vending apparatus and methods of vending
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment